Willy Baccaglini, Urologic Oncologist at Hospital Israelita Albert Einstein, shared a post on LinkedIn about a recent article by Hatice Bolek, et al published in The Oncologist
“This meta-analysis delivers the clarity the field has been waiting for.
By integrating CONTACT-03 and TiNivo-2, it demonstrates that immunotherapy rechallenge after prior ICI exposure in metastatic RCC does not translate into meaningful clinical benefit and may increase toxicity.
As our treatment landscape matures, the focus must shift from repeating immunotherapy to optimizing evidence-based sequencing strategies beyond first line.
High-quality randomized data should define practice—not habit or hope.”
Title: Immunotherapy Rechallenge in Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Clinical Trials
Authors: Hatice Bolek, Satı Coskun Yazgan, Emre Yekedüz, Bradley A McGregor, Rana R McKay, Sumanta K Pal, Toni K Choueiri, Yüksel Ürün
Read the Full Article on The Oncologist
More posts about Renal Cell Carcinoma